Ewopharma AG and Protina Pharmazeutische GmbH announce their new distribution partnership for Bulgaria. Ewopharma takes over market access and the targeted promotion of Protina’s brands Diasporal® and Basica® – two consumer health brands already established in Bulgaria. Building on its local distribution strength, its pharmacy and specialist physician network, and its longstanding market expertise, Ewopharma […]
continue reading
Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues to manage market access and the targeted promotion of Dr. Falk Pharma’s gastroenterological product portfolio through gastroenterologists across more than 10 markets in Central Eastern […]
continue reading
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. This recommendation supports sugemalimab for consolidation therapy in patients with unresectable Stage III non-small cell lung cancer (NSCLC), who have […]
continue reading
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a new indication for sugemalimab as monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC). This applies to patients whose tumours express […]
continue readingEffective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES category includes biodegradable polymer and polymer-free drug-eluting stents incorporating proprietary coatings and drug formulations to […]
continue reading
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention and treatment of allergies. As part of a succession solution, the Ewopharma Group was able […]
continue readingEwopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). These include EU member […]
continue reading
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In […]
continue reading